The 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026)

Denver, Colorado, US 22 February 2026 - 26 February 2026

Non-INSTI-based ART combination on the horizon for broad HIV population

20 Mar 2026 by

The investigational combination of doravirine plus islatravir (DOR/ISL)—a fixed-dose, once-daily oral antiretroviral therapy (ART) regimen that does not rely on integrase strand-transfer inhibitors (INSTIs)—is shaping up to be a promising alternative in the management of HIV, showing noninferiority to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in individuals initiating treatment for the first time and maintaining virologic suppression in those switching from various ART regimens, as shown in three phase III studies presented at CROI 2026.

Non-INSTI-based ART combination on the horizon for broad HIV population

20 Mar 2026

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

20 Mar 2026 by

A single-tablet regimen (STR) combining bictegravir and lenacapavir (BIC/LEN) was noninferior to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in maintaining virologic suppression among people with HIV (PWH) who are virologically suppressed, according to the ARTISTRY-2 trial presented at CROI 2026.

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

20 Mar 2026

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

19 Mar 2026 by

In adolescents with well-controlled HIV, switching from an oral antiretroviral therapy (ART) regimen to the long-acting injectable cabotegravir plus rilpivirine combination appears to be not only safe and efficacious in maintaining viral suppression but also strongly favoured, according to the end-of-study data from the phase I/II IMPAACT 2017 study.

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

19 Mar 2026

Pemivibart prevents COVID-19 in people with advanced HIV

18 Mar 2026 by

Individuals living with advanced HIV infection who received pemivibart demonstrate good tolerability, with no cases of RT-PCR-confirmed symptomatic COVID-19 reported through month 6, as shown by the results of a subgroup analysis of the CANOPY study.

Pemivibart prevents COVID-19 in people with advanced HIV

18 Mar 2026

Viral load, ART regimen predict mortality in infants born to mothers living with HIV

18 Mar 2026 by

Several infants born to mothers living with HIV die within 50 weeks, and some of the factors that may contribute to infant death include lower maternal CD4 count, higher viral load, and maternal antiretroviral (ART) regimen, among others, suggests a study presented at CROI 2026.

Viral load, ART regimen predict mortality in infants born to mothers living with HIV

18 Mar 2026

DTG/3TC tied to lower steatotic liver disease rates in PLWH

17 Mar 2026 by

Switching to dolutegravir/lamivudine (DTG/3TC) was associated with a significantly lower rate of steatotic liver disease (SLD) compared with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people living with HIV (PLWH), according to a subgroup analysis of the PASO DOBLE trial presented at CROI 2026.

DTG/3TC tied to lower steatotic liver disease rates in PLWH

17 Mar 2026

Pitavastatin cuts hypertension risk in PLWH

06 Mar 2026 by

In the secondary analysis of the REPRIEVE trial presented at CROI 2026, pitavastatin reduced the risk of developing incident hypertension in people living with HIV (PLWH).

Pitavastatin cuts hypertension risk in PLWH

06 Mar 2026

ARTISTRY-1 supports switch from complex HIV regimen to a novel single pill

04 Mar 2026 by

The phase II/III open-label ARTISTRY-1 trial shows that people living with HIV (PWH) may simplify their complex regimen (CR) by switching to a novel daily single-tablet regimen (STR) comprising bictegravir and lenacapavir (BIC+LEN).

ARTISTRY-1 supports switch from complex HIV regimen to a novel single pill

04 Mar 2026